

SynAct Pharma – executive interview

In this interview, we speak with [SynAct Pharma](#) CEO Jeppe Øvlesen and CBO Mads Bjerregaard about the strong momentum generated at the BIO International Convention in San Diego and what it means for the partnering prospects for lead asset resomelagon. They discuss the strong interest from global pharmaceutical companies following the ADVANCE Phase IIb data, why resomelagon's differentiated non-immunosuppressive profile is resonating with potential partners and how the asset's opportunity extends well beyond rheumatoid arthritis. They also discuss the upcoming FDA and EMA end-of-Phase II meetings, the evolving partnering process and the key catalysts that could shape SynAct's next phase of value creation.

